{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:26:44Z","timestamp":1792099604340,"version":"4.4.0"},"reference-count":0,"publisher":"Bentham Science Publishers Ltd.","issue":"4","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CPR"],"published-print":{"date-parts":[[2021,1,21]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Pneumonia is an acute infection of the lung parenchyma that is differentiated\namong three main diagnoses: community-acquired pneumonia (CAP), hospital-acquired pneumonia\n(HAP), and healthcare-associated pneumonia (HCAP). Though CAP is initially presented as\na mild infection, it contributes to childhood mortality rates globally. A vast number of pathogens\nare the cause of CAP, but the two main causative organisms include Streptococcus pneumoniae\nand Haemophilus influenzae, with the former causing up to 50% of all childhood cases. In the current\ntreatment guidelines from the Infectious Diseases Society of America (IDSA), amoxicillin is\nthe recommended treatment choice for mild-to-moderate CAP while ampicillin is recommended\nfor cases of severe CAP. Previous studies compared treatment between macrolides and beta-lactams\nto provide more information on the effectiveness in the pediatric population.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objective:<\/jats:title>\n<jats:p>The objective of this article is to systematically review the literature on the comparative\nefficacy of beta-lactams and macrolides in the treatment of community-acquired pneumonia among\nchildren and to evaluate the outcomes that are used to determine drug efficacy in order to provide\nmedication recommendations.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>A systematic literature search was conducted in PubMed, TRIP, Cochrane and SCOPUS.\nCohort studies and randomized controlled trials between the years 2000 and 2020 that compared\nthe efficacy of amoxicillin and macrolides in treating pediatric pneumonia were included in the systematic\nreview. Eligible patients included patients who were 17 years and younger, diagnosed with\ncommunity-acquired pneumonia, and were given beta-lactams or macrolides, either as monotherapy\nor combination. Two reviewers were involved in the appraisal process to assess the quality of\nthe methods used in the selected studies.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>A total of six articles were eligible according to the inclusion criteria and quality assessment.\nFour articles compared beta-lactam monotherapy with beta-lactam and macrolide combination\ntherapy, while Kogan R et al. compared macrolide therapy monotherapy with beta-lactam and\nmacrolide combination therapy and Leyenaar JK et al. compared ceftriaxone monotherapy to ceftriaxone\nplus macrolide combination therapy. The studies defined treatment failure as either a change\nin antibiotic therapy or hospital admission within 14 days of CAP diagnosis. Three studies used the\nlength of hospital stay as their primary outcome for comparison of treatment efficacy. Four studies\nshowed that the use of macrolides provided better treatment outcomes by reducing hospital stay\nand treatment failure rates. Beta-lactam and macrolide combination therapy did not show a significant\neffect on treatment failure compared to beta-lactam monotherapy regimens and it did not affect\nmortality compared to placebo or diet alone. Within the macrolide class, azithromycin was\nmore clinically significant compared to erythromycin.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>The use of macrolides as monotherapy or add-on therapy to beta-lactams is more effective\nin the treatment of community-acquired pneumonia in the pediatric population.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1573396316666200907115800","type":"journal-article","created":{"date-parts":[[2020,9,8]],"date-time":"2020-09-08T04:16:10Z","timestamp":1599538570000},"page":"307-313","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Comparative Efficacy of Beta-Lactams and Macrolides in the Treatment of Pediatric Pneumonia: A Systematic Review"],"prefix":"10.2174","volume":"16","author":[{"given":"Dalia","family":"Al Saeedy","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice, College of Pharmacy, Gulf Medical University, Ajman, United Arab Emirates"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed Wasif","family":"Gillani","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Gulf Medical University, Ajman, United Arab Emirates"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jumana","family":"Al-Salloum","sequence":"additional","affiliation":[{"name":"Clinical Preceptor, Thumbay Hospital, Ajman, United Arab Emirates"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arzu","family":"Moosvi","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Virginia Commonwealth University, Richmond, Virginia, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Eissa","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shabaz Mohiuddin","family":"Gulam","sequence":"additional","affiliation":[{"name":"Clinical Preceptor, Thumbay Hospital, Ajman, United Arab Emirates"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","container-title":["Current Pediatric Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/185658","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/185658\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eurekaselect.com\/article\/download\/185658","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,6]],"date-time":"2021-12-06T15:29:28Z","timestamp":1638804568000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/185658\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,21]]},"references-count":0,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,1,21]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1573396316666200907115800","relation":{},"ISSN":["1573-3963"],"issn-type":[{"value":"1573-3963","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1,21]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2020-05-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-07","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-01-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}